Company Announces One-for-Fifty Reverse Stock Split Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on August 07, 2015 San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, August 04, 2015 –Linkhere. AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today […]
28 July 2015. Link here. SeaDragon Limited (NZX:SEA) today releases an update to the market detailing the company’s progress towards completing the Omega-3 production plant. The update also includes an overview of; • Key products • Customers • The rationale for investment in SeaDragon • The use of proceeds • Financial forecasts • Sustainability statement For […]
23 July 2015. Link here. First-in-class collaboration combining digital health with class leading inhaled medications Long term international supply agreement targeted at AstraZeneca’s patient support programs Adherium’s Smartinhaler proven to substantially improve medication adherence and health outcomes in adults and children New Zealand-based Adherium (NZ) Limited has entered a long term partnership with international pharmaceutical leader […]
22 July 2015 – link here. Letter from the CEO.
20 July 2015. Link here.
20 July 2015, link here. Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheel-chair users, is pleased to announce that it has today signed a new agreement for a partnership in China with MAAB Group, an investment and trading company that specialises in sourcing and introducing innovative […]
20 July 2015 – Link here.
DUBLIN, Ireland, July 7, 2015 (GLOBE NEWSWIRE) — Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the signing of a research and development agreement with leading Japanese animal health company Zenoaq (Nippon Zenyaku Kogyo Co., Ltd.) to develop a number of therapeutic biologics for companion animals. The biologics will target undisclosed proteins involved […]
6 July 2015. Link here for ASX announcement. Demonstrates 78% Repigmentation compared to 0% in Control Groups.
30 June 2015. Link here. SeaDragon annual report, including audited financial statements, for the year to 31 March 2015.